Finally, whether inhibition of NF-κB might promote cancer in some cases by affecting tumor-suppressing activity of NF-κB or by having a detrimental effect on patient antitumor T cell immunity (natural or induced by immunotherapy) is not clear. The gene discussed is NFKB1; the disease is cancer.